A p53 codon 72 polymorphism associated with prostate cancer development and progression in Japanese.
An association between the Pro/Pro genotype of p53 codon 72 and a lower risk of prostate cancer in Caucasians was recently reported. However, the association of this polymorphism with prostate cancer risk in a Japanese population has not been clarified. We performed a case-control study consisting of 114 prostate cancer patients and 105 noncancer controls. Sixty-nine percent (79 of 114) of the patients had a positive family history. The genotypic frequencies in the controls were 39.0% for Arg/Arg, 54.3% for Arg/Pro and 6.7% for Pro/Pro; they were in Hardy-Weinberg equilibrium. When a comparison of the distribution of the p53 codon 72 polymorphism was made between patients with a first-degree family history and all control subjects, the adjusted odds ratios (ORs) for prostate cancer associated with the Arg/Arg, Arg/Pro and Pro/Pro genotypes were 1.00, 0.99 [95% confidence interval (CI) 0.53-1.88] and 2.80 (95% CI 1.04-7.53), respectively. When stratification of cases was performed based on clinical stage (localized or metastatic cancer) and pathological grade (a Gleason score of <7 or > or =7), there tended to be a greater number of patients with localized cancers among those patients with the Arg/Pro genotype than among those with the Arg/Arg genotype (overall cases: age-adjusted OR 0.36, 95% CI 0.13-1.00, p = 0.049; positive family history cases: age-adjusted OR 0.25, 95% CI 0.075-0.84, p = 0.025). In addition, there tended to be a greater number of patients with low-grade cancers among those with the Pro/Pro genotype than among those with other genotypes (overall cases: age-adjusted OR 0.41, 95% CI 0.13-1.30, p = 0.13; positive family history cases: age-adjusted OR 0.20, 95% CI 0.004-0.89, p = 0.035). The present findings suggest that the Pro/Pro genotype of p53 codon 72 played a role in prostate cancer susceptibility in a Japanese population. However, the Pro allele did not appear to worsen such clinical parameters as clinical stage or pathological grade.
Suzuki
Kazuhiro
K
Department of Urology, Gunma University School of Medicine, Maebashi, Gunma, Japan. kazu@showa.gunma-u.ac.jp
Matsui
Hiroshi
H
Ohtake
Nobuaki
N
Nakata
Seiji
S
Takei
Tomoyuki
T
Nakazato
Haruki
H
Okugi
Hironobu
H
Koike
Hidekazu
H
Ono
Yoshihiro
Y
Ito
Kazuto
K
Kurokawa
Kohei
K
Yamanaka
Hidetoshi
H
D000328:Adult; D000368:Aged; D044466:Asian People; D016022:Case-Control Studies; D003062:Codon; D018450:Disease Progression; D016158:Genes, p53; D020022:Genetic Predisposition to Disease; D005838:Genotype; D006801:Humans; D008297:Male; D008875:Middle Aged; D011110:Polymorphism, Genetic; D011471:Prostatic Neoplasms / Q000235:genetics* / Q000473:pathology / Q000503:physiopathology; D016159:Tumor Suppressor Protein p53; D001749:Urinary Bladder Neoplasms / Q000235:genetics*
D003062:Codon; D016159:Tumor Suppressor Protein p53